Skip to main content

Table 4 Bleeding characteristics and clinical outcome of patients in the UI-EWD monotherapy group

From: Hemostatic efficacy and safety of the hemostatic powder UI-EWD in patients with lower gastrointestinal bleeding

Variables UI-EWD monotherapy (n = 17)
Location of bleeding, n (%)
Hepatic flexure 2 (11.8)
Transverse colon 3 (17.6)
Sigmoid colon 4 (23.5)
Rectum 8 (47.6)
Cause of bleeding, n (%)
Ulcer bleeding 2 (11.8)
Post procedure bleeding 10 (58.8)
Tumor bleeding 5 (29.4)
Size of bleeding site, n (%)
 < 1 cm 1 (5.9)
1–4 cm 10 (58.8)
 > 4 cm 6 (35.3)
Forrest classification, n (%)
Ia 0 (0.0)
Ib 17 (100.0)
Cumulative re-bleeding, n (%)
At 7 days 0 (0.0)
At 14 days 0 (0.0)
At 28 days 0 (0.0)
Time to re-bleeding (days)§
Adverse event, n (%)
Colonic obstruction 0 (0.0)
Perforation 0 (0.0)
Infection 0 (0.0)
Embolization 0 (0.0)
  1. §Median (range)
  2. +Fisher’s exact test
  3. *P-values were calculated using the t-test or Fisher calculated using the of the conventional therapy group and the UI-EWD therapy group